The Experts below are selected from a list of 39411 Experts worldwide ranked by ideXlab platform
J Wedam - One of the best experts on this subject based on the ideXlab platform.
-
field trials of an oral calcium Propionate paste as an aid to prevent milk fever in periparturient dairy cows
Journal of Dairy Science, 1996Co-Authors: Jesse P. Goff, P W Jardon, Ronald L Horst, Claudia Borelli, J WedamAbstract:Abstract Trials were conducted to test the efficacy of a calcium Propionate paste as an aid to prevent milk fever and to improve the health of dairy cows. Each calcium Propionate treatment tube supplied 37g of calcium. In trials involving Holstein herds and a Jersey herd, two (trials 1 and 2) or three (trial 3) calcium Propionate tubes were given at calving and again at 12h after calving. For the Jersey herd, calcium Propionate treatment (two tubes) reduced the incidence of milk fever from 50% in control cows to 29% in treated cows. Plasma obtained 24h after calving from treated cows had higher calcium, lower NEFA, and lower β -hydroxybutyrate concentrations than did plasma from control cows. No other benefits of calcium Propionate treatment were significant for health or for productivity of the cows. Calcium Propionate treatment had no significant effects on blood calcium, NEFA, or s-hydroxybutyrate in the Holstein herds studied. However, calcium Propionate did reduce the number of cows with subclinical hypocalcemia (≤7.5 mg/dl of plasma calcium) at 24h after calving in both trials involving Holstein cows. Calcium Propionate treatment was beneficial in reducing subclinical hypocalcemia in all trials and reduced the incidence of milk fever in a herd having a problem with milk fever.
-
Field trials of an oral calcium Propionate paste as an aid to prevent milk fever in periparturient dairy cows.
Journal of dairy science, 1996Co-Authors: Jesse P. Goff, P W Jardon, Ronald L Horst, Claudia Borelli, J WedamAbstract:Trials were conducted to test the efficacy of a calcium Propionate paste as an aid to prevent milk fever and to improve the health of dairy cows. Each calcium Propionate treatment tube supplied 37 g of calcium. In trials involving Holstein herds and a Jersey herd, two (trials 1 and 2) or three (trial 3) calcium Propionate tubes were given at calving and again at 12 h after calving. For the Jersey herd, calcium Propionate treatment (two tubes) reduced the incidence of milk fever from 50% in control cows to 29% in treated cows. Plasma obtained 24 h after calving from treated cows had higher calcium, lower NEFA, and lower beta-hydroxybutyrate concentrations than did plasma from control cows. No other benefits of calcium Propionate treatment were significant for health or for productivity of the cows. Calcium Propionate treatment had no significant effects on blood calcium, NEFA, or beta-hydroxybutyrate in the Holstein herds studied. However, calcium Propionate did reduce the number of cows with subclinical hypocalcemia (< or = 7.5 mg/dl of plasma calcium) at 24 h after calving in both trials involving Holstein cows. Calcium Propionate treatment was beneficial in reducing subclinical hypocalcemia in all trials and reduced the incidence of milk fever in a herd having a problem with milk fever.
Courtney J Duckworth - One of the best experts on this subject based on the ideXlab platform.
-
correction to 1 13 c Propionate breath testing as a surrogate endpoint to assess efficacy of liver directed therapies in methylmalonic acidemia mma
Genetics in Medicine, 2021Co-Authors: Irini Manoli, Alexandra Pass, Elizabeth Harrington, Jennifer L Sloan, Jack Gagne, Samantha Mccoy, Sarah L Bell, Jacob D Hattenbach, Brooks P Leitner, Courtney J DuckworthAbstract:To develop a safe and noninvasive in vivo assay of hepatic Propionate oxidative capacity. A modified 1-13C-Propionate breath test was administered to 57 methylmalonic acidemia (MMA) subjects, including 19 transplant recipients, and 16 healthy volunteers. Isotopomer enrichment (13CO2/12CO2) was measured in exhaled breath after an enteral bolus of sodium-1-13C-Propionate, and normalized for CO2 production. 1-13C-Propionate oxidation was then correlated with clinical, laboratory, and imaging parameters collected via a dedicated natural history protocol. Lower Propionate oxidation was observed in patients with the severe mut0 and cblB subtypes of MMA, but was near normal in those with the cblA and mut− forms of the disorder. Liver transplant recipients demonstrated complete restoration of 1-13C-Propionate oxidation to control levels. 1-13C-Propionate oxidation correlated with cognitive test result, growth indices, bone mineral density, renal function, and serum biomarkers. Test repeatability was robust in controls and in MMA subjects (mean coefficient of variation 6.9% and 12.8%, respectively), despite widely variable serum methylmalonic acid concentrations in the patients. Propionate oxidative capacity, as measured with 1-13C-Propionate breath testing, predicts disease severity and clinical outcomes, and could be used to assess the therapeutic effects of liver-targeted genomic therapies for MMA and related disorders of Propionate metabolism. This clinical study is registered in www.clinicaltrials.gov with the ID: NCT00078078. Study URL: http://clinicaltrials.gov/ct2/show/NCT00078078
-
1 13c Propionate breath testing as a surrogate endpoint to assess efficacy of liver directed therapies in methylmalonic acidemia mma
Genetics in Medicine, 2021Co-Authors: Irini Manoli, Alexandra Pass, Elizabeth Harrington, Jennifer L Sloan, Jack Gagne, Samantha Mccoy, Sarah L Bell, Jacob D Hattenbach, Brooks P Leitner, Courtney J DuckworthAbstract:To develop a safe and noninvasive in vivo assay of hepatic Propionate oxidative capacity. A modified 1-13C-Propionate breath test was administered to 57 methylmalonic acidemia (MMA) subjects, including 19 transplant recipients, and 16 healthy volunteers. Isotopomer enrichment (13CO2/12CO2) was measured in exhaled breath after an enteral bolus of sodium-1-13C-Propionate, and normalized for CO2 production. 1-13C-Propionate oxidation was then correlated with clinical, laboratory, and imaging parameters collected via a dedicated natural history protocol. Lower Propionate oxidation was observed in patients with the severe mut0 and cblB subtypes of MMA, but was near normal in those with the cblA and mut− forms of the disorder. Liver transplant recipients demonstrated complete restoration of 1-13C-Propionate oxidation to control levels. 1-13C-Propionate oxidation correlated with cognitive test result, growth indices, bone mineral density, renal function, and serum biomarkers. Test repeatability was robust in controls and in MMA subjects (mean coefficient of variation 6.9% and 12.8%, respectively), despite widely variable serum methylmalonic acid concentrations in the patients. Propionate oxidative capacity, as measured with 1-13C-Propionate breath testing, predicts disease severity and clinical outcomes, and could be used to assess the therapeutic effects of liver-targeted genomic therapies for MMA and related disorders of Propionate metabolism. This clinical study is registered in www.clinicaltrials.gov with the ID: NCT00078078. Study URL: http://clinicaltrials.gov/ct2/show/NCT00078078
-
1 13 c Propionate breath testing as a surrogate endpoint to assess efficacy of liver directed therapies in methylmalonic acidemia mma
Genetics in Medicine, 2021Co-Authors: Irini Manoli, Alexandra Pass, Elizabeth Harrington, Jennifer L Sloan, Jack Gagne, Samantha Mccoy, Sarah L Bell, Jacob D Hattenbach, Brooks P Leitner, Courtney J DuckworthAbstract:To develop a safe and noninvasive in vivo assay of hepatic Propionate oxidative capacity. A modified 1-13C-Propionate breath test was administered to 57 methylmalonic acidemia (MMA) subjects, including 19 transplant recipients, and 16 healthy volunteers. Isotopomer enrichment (13CO2/12CO2) was measured in exhaled breath after an enteral bolus of sodium-1-13C-Propionate, and normalized for CO2 production. 1-13C-Propionate oxidation was then correlated with clinical, laboratory, and imaging parameters collected via a dedicated natural history protocol. Lower Propionate oxidation was observed in patients with the severe mut0 and cblB subtypes of MMA, but was near normal in those with the cblA and mut− forms of the disorder. Liver transplant recipients demonstrated complete restoration of 1-13C-Propionate oxidation to control levels. 1-13C-Propionate oxidation correlated with cognitive test result, growth indices, bone mineral density, renal function, and serum biomarkers. Test repeatability was robust in controls and in MMA subjects (mean coefficient of variation 6.9% and 12.8%, respectively), despite widely variable serum methylmalonic acid concentrations in the patients. Propionate oxidative capacity, as measured with 1-13C-Propionate breath testing, predicts disease severity and clinical outcomes, and could be used to assess the therapeutic effects of liver-targeted genomic therapies for MMA and related disorders of Propionate metabolism. This clinical study is registered in www.clinicaltrials.gov with the ID: NCT00078078. Study URL: http://clinicaltrials.gov/ct2/show/NCT00078078
Jesse P. Goff - One of the best experts on this subject based on the ideXlab platform.
-
field trials of an oral calcium Propionate paste as an aid to prevent milk fever in periparturient dairy cows
Journal of Dairy Science, 1996Co-Authors: Jesse P. Goff, P W Jardon, Ronald L Horst, Claudia Borelli, J WedamAbstract:Abstract Trials were conducted to test the efficacy of a calcium Propionate paste as an aid to prevent milk fever and to improve the health of dairy cows. Each calcium Propionate treatment tube supplied 37g of calcium. In trials involving Holstein herds and a Jersey herd, two (trials 1 and 2) or three (trial 3) calcium Propionate tubes were given at calving and again at 12h after calving. For the Jersey herd, calcium Propionate treatment (two tubes) reduced the incidence of milk fever from 50% in control cows to 29% in treated cows. Plasma obtained 24h after calving from treated cows had higher calcium, lower NEFA, and lower β -hydroxybutyrate concentrations than did plasma from control cows. No other benefits of calcium Propionate treatment were significant for health or for productivity of the cows. Calcium Propionate treatment had no significant effects on blood calcium, NEFA, or s-hydroxybutyrate in the Holstein herds studied. However, calcium Propionate did reduce the number of cows with subclinical hypocalcemia (≤7.5 mg/dl of plasma calcium) at 24h after calving in both trials involving Holstein cows. Calcium Propionate treatment was beneficial in reducing subclinical hypocalcemia in all trials and reduced the incidence of milk fever in a herd having a problem with milk fever.
-
Field trials of an oral calcium Propionate paste as an aid to prevent milk fever in periparturient dairy cows.
Journal of dairy science, 1996Co-Authors: Jesse P. Goff, P W Jardon, Ronald L Horst, Claudia Borelli, J WedamAbstract:Trials were conducted to test the efficacy of a calcium Propionate paste as an aid to prevent milk fever and to improve the health of dairy cows. Each calcium Propionate treatment tube supplied 37 g of calcium. In trials involving Holstein herds and a Jersey herd, two (trials 1 and 2) or three (trial 3) calcium Propionate tubes were given at calving and again at 12 h after calving. For the Jersey herd, calcium Propionate treatment (two tubes) reduced the incidence of milk fever from 50% in control cows to 29% in treated cows. Plasma obtained 24 h after calving from treated cows had higher calcium, lower NEFA, and lower beta-hydroxybutyrate concentrations than did plasma from control cows. No other benefits of calcium Propionate treatment were significant for health or for productivity of the cows. Calcium Propionate treatment had no significant effects on blood calcium, NEFA, or beta-hydroxybutyrate in the Holstein herds studied. However, calcium Propionate did reduce the number of cows with subclinical hypocalcemia (< or = 7.5 mg/dl of plasma calcium) at 24 h after calving in both trials involving Holstein cows. Calcium Propionate treatment was beneficial in reducing subclinical hypocalcemia in all trials and reduced the incidence of milk fever in a herd having a problem with milk fever.
Irini Manoli - One of the best experts on this subject based on the ideXlab platform.
-
correction to 1 13 c Propionate breath testing as a surrogate endpoint to assess efficacy of liver directed therapies in methylmalonic acidemia mma
Genetics in Medicine, 2021Co-Authors: Irini Manoli, Alexandra Pass, Elizabeth Harrington, Jennifer L Sloan, Jack Gagne, Samantha Mccoy, Sarah L Bell, Jacob D Hattenbach, Brooks P Leitner, Courtney J DuckworthAbstract:To develop a safe and noninvasive in vivo assay of hepatic Propionate oxidative capacity. A modified 1-13C-Propionate breath test was administered to 57 methylmalonic acidemia (MMA) subjects, including 19 transplant recipients, and 16 healthy volunteers. Isotopomer enrichment (13CO2/12CO2) was measured in exhaled breath after an enteral bolus of sodium-1-13C-Propionate, and normalized for CO2 production. 1-13C-Propionate oxidation was then correlated with clinical, laboratory, and imaging parameters collected via a dedicated natural history protocol. Lower Propionate oxidation was observed in patients with the severe mut0 and cblB subtypes of MMA, but was near normal in those with the cblA and mut− forms of the disorder. Liver transplant recipients demonstrated complete restoration of 1-13C-Propionate oxidation to control levels. 1-13C-Propionate oxidation correlated with cognitive test result, growth indices, bone mineral density, renal function, and serum biomarkers. Test repeatability was robust in controls and in MMA subjects (mean coefficient of variation 6.9% and 12.8%, respectively), despite widely variable serum methylmalonic acid concentrations in the patients. Propionate oxidative capacity, as measured with 1-13C-Propionate breath testing, predicts disease severity and clinical outcomes, and could be used to assess the therapeutic effects of liver-targeted genomic therapies for MMA and related disorders of Propionate metabolism. This clinical study is registered in www.clinicaltrials.gov with the ID: NCT00078078. Study URL: http://clinicaltrials.gov/ct2/show/NCT00078078
-
1 13c Propionate breath testing as a surrogate endpoint to assess efficacy of liver directed therapies in methylmalonic acidemia mma
Genetics in Medicine, 2021Co-Authors: Irini Manoli, Alexandra Pass, Elizabeth Harrington, Jennifer L Sloan, Jack Gagne, Samantha Mccoy, Sarah L Bell, Jacob D Hattenbach, Brooks P Leitner, Courtney J DuckworthAbstract:To develop a safe and noninvasive in vivo assay of hepatic Propionate oxidative capacity. A modified 1-13C-Propionate breath test was administered to 57 methylmalonic acidemia (MMA) subjects, including 19 transplant recipients, and 16 healthy volunteers. Isotopomer enrichment (13CO2/12CO2) was measured in exhaled breath after an enteral bolus of sodium-1-13C-Propionate, and normalized for CO2 production. 1-13C-Propionate oxidation was then correlated with clinical, laboratory, and imaging parameters collected via a dedicated natural history protocol. Lower Propionate oxidation was observed in patients with the severe mut0 and cblB subtypes of MMA, but was near normal in those with the cblA and mut− forms of the disorder. Liver transplant recipients demonstrated complete restoration of 1-13C-Propionate oxidation to control levels. 1-13C-Propionate oxidation correlated with cognitive test result, growth indices, bone mineral density, renal function, and serum biomarkers. Test repeatability was robust in controls and in MMA subjects (mean coefficient of variation 6.9% and 12.8%, respectively), despite widely variable serum methylmalonic acid concentrations in the patients. Propionate oxidative capacity, as measured with 1-13C-Propionate breath testing, predicts disease severity and clinical outcomes, and could be used to assess the therapeutic effects of liver-targeted genomic therapies for MMA and related disorders of Propionate metabolism. This clinical study is registered in www.clinicaltrials.gov with the ID: NCT00078078. Study URL: http://clinicaltrials.gov/ct2/show/NCT00078078
-
1 13 c Propionate breath testing as a surrogate endpoint to assess efficacy of liver directed therapies in methylmalonic acidemia mma
Genetics in Medicine, 2021Co-Authors: Irini Manoli, Alexandra Pass, Elizabeth Harrington, Jennifer L Sloan, Jack Gagne, Samantha Mccoy, Sarah L Bell, Jacob D Hattenbach, Brooks P Leitner, Courtney J DuckworthAbstract:To develop a safe and noninvasive in vivo assay of hepatic Propionate oxidative capacity. A modified 1-13C-Propionate breath test was administered to 57 methylmalonic acidemia (MMA) subjects, including 19 transplant recipients, and 16 healthy volunteers. Isotopomer enrichment (13CO2/12CO2) was measured in exhaled breath after an enteral bolus of sodium-1-13C-Propionate, and normalized for CO2 production. 1-13C-Propionate oxidation was then correlated with clinical, laboratory, and imaging parameters collected via a dedicated natural history protocol. Lower Propionate oxidation was observed in patients with the severe mut0 and cblB subtypes of MMA, but was near normal in those with the cblA and mut− forms of the disorder. Liver transplant recipients demonstrated complete restoration of 1-13C-Propionate oxidation to control levels. 1-13C-Propionate oxidation correlated with cognitive test result, growth indices, bone mineral density, renal function, and serum biomarkers. Test repeatability was robust in controls and in MMA subjects (mean coefficient of variation 6.9% and 12.8%, respectively), despite widely variable serum methylmalonic acid concentrations in the patients. Propionate oxidative capacity, as measured with 1-13C-Propionate breath testing, predicts disease severity and clinical outcomes, and could be used to assess the therapeutic effects of liver-targeted genomic therapies for MMA and related disorders of Propionate metabolism. This clinical study is registered in www.clinicaltrials.gov with the ID: NCT00078078. Study URL: http://clinicaltrials.gov/ct2/show/NCT00078078
Andreas Seidelmorgenstern - One of the best experts on this subject based on the ideXlab platform.
-
solubility study and thermal stability analysis of calcium Propionate
Chemical Engineering & Technology, 2017Co-Authors: Heike Lorenz, Andreas SeidelmorgensternAbstract:Solubilities in water and ethanol-water mixtures as well as the thermal behavior of the food additive calcium Propionate were investigated to clarify deviations in published data. Material purified by recrystallization was used to exclude influence of impurities. Investigation of the dissociation process of calcium Propionate in aqueous solution indicated that the particular shapes of the solubility curves cannot be attributed to changes in pH. The substance purchased turned out to be a mixture of the monohydrate and anhydrous calcium Propionate. A new polymorph of the anhydrous calcium Propionate was found and characterized. The results provide a better understanding of calcium Propionate and support the development of improved crystallization processes.
